Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Rosiglitazone Therapy of Diabetes Mellitus in Acromegaly Causes Significant Reduction of Growth Hormone and Insulin-like Growth Hormone I Secretion (CROSBI ID 133145)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Gradišer, Marina ; Matovinović, Martina ; Vrkljan, Milan Rosiglitazone Therapy of Diabetes Mellitus in Acromegaly Causes Significant Reduction of Growth Hormone and Insulin-like Growth Hormone I Secretion // Endocrinologist, 17 (2007), 4; 204-205-x

Podaci o odgovornosti

Gradišer, Marina ; Matovinović, Martina ; Vrkljan, Milan

engleski

Rosiglitazone Therapy of Diabetes Mellitus in Acromegaly Causes Significant Reduction of Growth Hormone and Insulin-like Growth Hormone I Secretion

We presented woman with acromegaly and diabetes mellitus. Transsphenoidal resection of the macroadenoma confirmed histologically a GH-secreting pituitary adenoma. Since the removal of the tumor was incomplete, medical therapy was instituted. A PPAR-gama agonist was administered to treat residual diabetes.Suprisengly, there was improvement in acromegaly features with decrease levels of GH and IGF-I.

rosiglitazone; acromegaly; diabetes mellitus

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

17 (4)

2007.

204-205-x

objavljeno

1051-2144

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost